Loading...
•
Jun 30, 2024
Collegium Q2 2024 Earnings Report
Collegium reported strong Q2 2024 financial results, driven by record Belbuca revenue and disciplined expense management.
Key Takeaways
Collegium Pharmaceutical, Inc. reported a 7% increase in product revenues, net, reaching $145.3 million for Q2 2024. GAAP net income increased by 51% year-over-year to $19.6 million, and adjusted EBITDA rose by 12% to $96.0 million. The company reaffirmed its full-year 2024 guidance and is on track to close the acquisition of Ironshore Therapeutics in Q3 2024.
Net revenue for Q2 2024 was $145.3 million.
Belbuca revenue reached a record $52.2 million, up 21% year-over-year.
GAAP net income for Q2 2024 was $19.6 million, a 51% increase year-over-year.
Adjusted EBITDA for Q2 2024 was $96.0 million, up 12% year-over-year.
Forward Guidance
Collegium reaffirmed its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA for its current business, not including the impact of the planned acquisition of Ironshore.
Positive Outlook
- Product Revenues, Net: $580.0 to $595.0 million
- Adjusted Operating Expenses (Excluding Stock-Based Compensation): $120.0 to $125.0 million
- Adjusted EBITDA (Excluding Stock-Based Compensation): $380.0 to $395.0 million
- Acquisition of Ironshore Therapeutics expected to close in Q3 2024
- Acquisition expected to be immediately accretive to adjusted EBITDA.
Challenges Ahead
- Full-year 2024 guidance does not include the impact of the planned acquisition of Ironshore.
- The company expects to update guidance to include Ironshore after closing of the acquisition.
- Uncertainty regarding successful integration of Ironshore's operations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...